Advisor OS LLC Acquires 82 Shares of Novo Nordisk A/S (NYSE:NVO)

Advisor OS LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 0.6% during the second quarter, Holdings Channel reports. The institutional investor owned 13,972 shares of the company’s stock after buying an additional 82 shares during the quarter. Advisor OS LLC’s holdings in Novo Nordisk A/S were worth $1,994,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in NVO. Aveo Capital Partners LLC acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $205,000. 9258 Wealth Management LLC grew its holdings in Novo Nordisk A/S by 4.0% during the fourth quarter. 9258 Wealth Management LLC now owns 2,513 shares of the company’s stock worth $260,000 after buying an additional 97 shares in the last quarter. Rollins Financial raised its position in Novo Nordisk A/S by 10.4% in the 4th quarter. Rollins Financial now owns 3,894 shares of the company’s stock valued at $403,000 after buying an additional 368 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Novo Nordisk A/S by 38.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 94,544 shares of the company’s stock valued at $9,781,000 after acquiring an additional 26,067 shares in the last quarter. Finally, Gryphon Financial Partners LLC purchased a new position in Novo Nordisk A/S during the 4th quarter worth $237,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $131.23 on Friday. The company’s 50 day moving average is $134.79 and its 200-day moving average is $132.47. The firm has a market cap of $588.90 billion, a P/E ratio of 45.25, a price-to-earnings-growth ratio of 1.52 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $86.96 and a 12-month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The business had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Sell-side analysts predict that Novo Nordisk A/S will post 3.11 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were given a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 24.83%.

Analysts Set New Price Targets

A number of research firms recently weighed in on NVO. The Goldman Sachs Group initiated coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Monday, August 19th. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, August 19th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $145.17.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.